PAB Stock Overview
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Patrys Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.009 |
52 Week High | AU$0.021 |
52 Week Low | AU$0.006 |
Beta | 0.36 |
1 Month Change | 0% |
3 Month Change | 12.50% |
1 Year Change | -57.14% |
3 Year Change | -67.86% |
5 Year Change | -59.09% |
Change since IPO | -98.58% |
Recent News & Updates
Recent updates
Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year
Nov 08Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?
Mar 24Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year
Nov 09Will Patrys (ASX:PAB) Spend Its Cash Wisely?
Sep 01Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?
May 11We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate
Sep 28We're Hopeful That Patrys (ASX:PAB) Will Use Its Cash Wisely
Jun 15Companies Like Patrys (ASX:PAB) Are In A Position To Invest In Growth
Mar 01What Can We Make Of Patrys' (ASX:PAB) CEO Compensation?
Jan 07Shareholder Returns
PAB | AU Biotechs | AU Market | |
---|---|---|---|
7D | 0% | 2.7% | 1.5% |
1Y | -57.1% | 1.4% | 11.6% |
Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 1.4% over the past year.
Return vs Market: PAB underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
PAB volatility | |
---|---|
PAB Average Weekly Movement | 16.5% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.7% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: PAB has not had significant price volatility in the past 3 months.
Volatility Over Time: PAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | n/a | James Campbell | https://www.patrys.com |
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.
Patrys Limited Fundamentals Summary
PAB fundamental statistics | |
---|---|
Market cap | AU$18.50m |
Earnings (TTM) | -AU$5.12m |
Revenue (TTM) | AU$1.70m |
10.9x
P/S Ratio-3.6x
P/E RatioIs PAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PAB income statement (TTM) | |
---|---|
Revenue | AU$1.70m |
Cost of Revenue | AU$0 |
Gross Profit | AU$1.70m |
Other Expenses | AU$6.82m |
Earnings | -AU$5.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0025 |
Gross Margin | 100.00% |
Net Profit Margin | -302.26% |
Debt/Equity Ratio | 0% |
How did PAB perform over the long term?
See historical performance and comparison